|

Sequential Gemcitabine and Jelmyto Treatment (Gem/Jel) Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Gemcitabine (endoluminal administration), Jelmyto (gel-based mitomycin, endoluminal administration)

Pipeline

Phase 2: 1

Top Sponsors

  • Rutgers, The State University of New Jersey1

Indications

  • Urinary Bladder Cancer1
  • Upper Tract Urothelial Cancer1
  • Urothelial Cancer1
  • Cancer1

New Brunswick, New Jersey1 trial

SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

Rutgers Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.